PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger, +23

PubMed

ImmunologyOral AdministrationPharmacotherapyTumor BiologyAngiogenesis +18

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Joachim Drevs, Ilse Hofmann, Harald Hugenschmidt, +7

PubMed

UrologyAngiogenesisOncologyPtk787/zk 222584Vessel Density +13

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger, +11

Journal of Clinical Oncology

Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound

Felix Kratz, André Warnecke, Karin Scheuermann, +12

Journal of Medicinal Chemistry

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

Beate Schultheis, Dirk Strumberg, Ansgar Santel, +8

Journal of Clinical Oncology

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

Ferry A.L.M. Eskens, Herlinde Dumez, Ronald Hoekstra, +7

European Journal of Cancer

OncologyPharmacologyAdvanced Solid TumoursTherapeutic EfficacyPharmacotherapy +5

PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Joachim Drevs, Ralph Müller-Driver, Christine Wittig, +9

PubMed

PathologyTumor BiologyAngiogenesisOncologyReceptor Tyrosine Kinase +20

A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.

Ahmed M. Mansour, Joachim Drevs, N. Esser, +5

PubMed

ImmunologyMalignant MelanomaMatrix Metalloproteinase 2Tumor BiologyAnti-cancer Agent +17

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

K. Mross, Joachim Drevs, M Müller, +10

European Journal of Cancer

HepatologyMedicineLiver PhysiologyHepatobiliary TumorSolid Tumours +7

A Novel Macromolecular Prodrug Concept Exploiting Endogenous Serum Albumin as a Drug Carrier for Cancer Chemotherapy

Felix Kratz, Ralph Müller-Driver, Inga Hofmann, +2

Journal of Medicinal Chemistry

Chemoprevention StrategyAltmetric Attention ScorePharmacotherapyCancer ChemotherapyTumor Biology +19